Managed Access Program (MAP) to Provide Access to Siponimod Treatment for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With no Satisfactory Alternative Treatment
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 09 Sep 2020 New trial record